Project Grant R21CA312387
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant totaling $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period June 1, 2026 through May 31, 2028. The research focuses on fragment-based targeting of epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor (EGFR)-mutant lung cancer. The project utilizes fragment-like chemical...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $687,593 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on May 12, 2026, with completion targeted for April 30, 2031. The award funds fundamental cancer biology research investigating cysteine acquisition and utilization mechanisms in lung adenocarcinoma. The research will deliver scientific insights into how tumor cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1.098 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on August 13, 2025, with a completion date of April 30, 2030. The funded research focuses on understanding the biological mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs) and their progression through various functional states, including...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Miami's Office of Research Administration - School of Medicine Division a $529,260 Project Grant on June 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate lactic acid sensing as a therapeutic vulnerability in clear cell renal cell carcinoma (CCRCC). The research examines the role of extracellular lactate in the tumor microenvironment and its function as a self-signal...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $730,097 to the Sloan-Kettering Institute for Cancer Research, effective May 1, 2026 through April 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project addresses the suppression of anti-tumor T-cell immunity in gastric adenocarcinoma by investigating how chronic inflammation induces KLF-2 (Krüppel-like factor 2)—a quiescence-associated transcription factor—in...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $682,495 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026 through May 31, 2031. The award funds fundamental research to characterize the SPOP-BRAF-MTORC1 signaling axis in melanoma pathogenesis. The research addresses therapeutic gaps for melanoma patients harboring wild-type or non-V600-mutated BRAF mutations,...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.49M Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective August 1, 2025, through July 31, 2030. This research initiative comprises three integrated projects investigating lipid metabolism as a determinant of ferroptosis sensitivity in cancer cells. Project 1, led by Dr. Xuejun Jiang at Memorial Sloan Kettering Cancer Institute, examines how...